GULF PHARMACEUTICAL INDUSTRIES |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.941 AED | -0.11% |
|
-1.98% | +22.37% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The group shows a rather high level of debt in proportion to its EBITDA.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +22.37% | 296M | C+ | ||
| +4.06% | 70.44B | A | ||
| +10.97% | 8.94B | A- | ||
| -14.44% | 4.75B | A- | ||
| +41.60% | 4.5B | - | ||
| +5.96% | 3.85B | B- | ||
| +23.46% | 2.38B | B | ||
| -19.32% | 2.34B | C- | ||
| -27.04% | 2.2B | - | ||
| +7.97% | 1.96B | - | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
- Stock Market
- Equities
- JULPHAR Stock
- Ratings Gulf Pharmaceutical Industries
